Schizophrenia: all 3,539 studies
Page 29 of 36. Open to participants first (473), then studies with results posted, then the rest; newest registration first within each.
- Treatment Response in Schizophrenia: Bridging Imaging and Postmortem StudiesCompletedNCT00937716
- Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) ScanningStatus unknownNCT00937261Phase 4
- Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With OlanzapineWithdrawnNCT00934908Not applicable
- Non-interventional Open Label Study to Investigate the Effect of Quetiapine XR on Patient Satisfaction and Quality of Life in Patients With SchizophreniaCompletedNCT00934726
- Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)CompletedNCT00934466Phase 1
- Feasibility of Providing Cognitive Remediation to People With Schizophrenia in a Clinical NetworkCompletedNCT00930150Phase 4
- Role of Anti-Inflammatory Agents in Patients With SchizophreniaCompletedNCT00929955Phase 1
- A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.TerminatedNCT00929370Phase 1
- Improving Representative Payeeship for People With Psychiatric Disabilities and Their FamiliesCompletedNCT00924976Not applicable
- A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate ExtendedCompletedNCT00922090
- Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia PatientsCompletedNCT00921804Phase 2
- Seroquel (Quetiapine Fumarate) InPractice Evaluation ProgrammeCompletedNCT00921362
- Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic PatientsCompletedNCT00919607Phase 1
- Polypharmacy in Clozapine-resistant SchizophreniaCompletedNCT00918021Phase 4
- Evaluation Study of New Compounds With Potential Use in SchizophreniaWithdrawnNCT00916201Phase 1
- A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With SchizophreniaCompletedNCT00915512Phase 4
- Extended Specialized Assertive Intervention for First Episode PsychosisCompletedNCT00914238Not applicable
- Visual Exploration and Attention: Studies in Patients With Schizophrenia and Autism Spectrum DisordersStatus unknownNCT00914030
- Cognitive Training to Improve Work Outcomes in Severe Mental IllnessCompletedNCT00895258Phase 2
- Study of a Neurocognition Enhancing Agent in Patients With SchizophreniaCompletedNCT00894842Phase 2/3
- Magnetoencephalographic (MEG) Correlates of Negative Symptoms in Patients Suffering From Schizophrenia and Their Influence by Add-on TreatmentsStatus unknownNCT00894296
- Effect of Add-on Citalopram to Risperidone on Negative Symptoms in SchizophreniaCompletedNCT00893256Phase 4
- A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS PaliperidoneCompletedNCT00892541Phase 1
- A Bioequivalence Study of 15 mg ER OROS PaliperidoneCompletedNCT00892489Phase 1
- A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese VolunteersCompletedNCT00892320Phase 1
- A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I DisorderCompletedNCT00892125Phase 1
- Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective DisorderWithdrawnNCT00892021Phase 1
- A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With SchizophreniaCompletedNCT00888693Phase 1
- A Shared Decision Making Training for Inpatients With SchizophreniaCompletedNCT00885716Not applicable
- Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)TerminatedNCT00885690Not applicable
- Prospective Studies of the Pathogenesis of SchizophreniaCompletedNCT00877552
- Multiple Dose Safety Study of PF-04802540 in Subjects With SchizophreniaCompletedNCT00876304Phase 1
- Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in SchizophreniaCompletedNCT00875498Not applicable
- Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With SchizophreniaCompletedNCT00873249
- Transcranial Direct Current Stimulation (tDCS) and Hallucinations in SchizophreniaCompletedNCT00870909Not applicable
- A Study To Evaluate The Efficacy And Safety Of Intramuscular Levosulpiride In Patients With Agitation Of SchizophreniaCompletedNCT00866645Phase 2/3
- Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With SchizophreniaCompletedNCT00864825Phase 4
- Sertindole in Asian Patients With SchizophreniaCompletedNCT00864045Phase 3
- Study of CYR-101 in Patients With SchizophreniaCompletedNCT00861796Phase 2
- Bifeprunox Extension to Extension Study in Patients With SchizophreniaTerminatedNCT00861497Phase 3
- An Adherence Study of Antipsychotic Medication in Outpatients With Schizophrenia or Schizoaffective DisorderStatus unknownNCT00861003
- Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in SchizophreniaCompletedNCT00859872Phase 4
- Subjective Well Being of Schizophrenic Patients in GreeceCompletedNCT00857064
- Risperidone Maintenance Treatment in SchizophreniaCompletedNCT00848432Phase 4
- Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset SchizophreniaCompletedNCT00847600Phase 4
- The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health CenterCompletedNCT00845572Not applicable
- A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.CompletedNCT00843687Phase 3
- A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS PaliperidoneCompletedNCT00838669Phase 1
- Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective DisorderWithdrawnNCT00838227Phase 2
- Cognitive Functioning Related to Job Tenure Among Patients With SchizophreniaCompletedNCT00838123
- Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With SchizophreniaStatus unknownNCT00838032Phase 4
- Effects of Antipsychotic Medications on Energy Intake and ExpenditureCompletedNCT00836251
- NIS to Observe Improvement in Global Assessment of Functioning in Patients With SchizophreniaCompletedNCT00833456
- Cognitive Behavioral Social Skills Training for Patients With Late-Life Schizophrenia: a Pilot StudyCompletedNCT00832845Not applicable
- Cognitive Training to Enhance VA Work Program OutcomesCompletedNCT00829400Not applicable
- Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.CompletedNCT00828958Phase 3
- Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With SchizophreniaCompletedNCT00827840Phase 4
- Pharmacodynamic/Pharmacokinetic Study of AQW051 in SchizophreniaCompletedNCT00825539Phase 1/2
- Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With SchizophreniaStatus unknownNCT00825045Not applicable
- Study of Mental Care in SpainCompletedNCT00824031
- Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With SchizophreniaCompletedNCT00821600Phase 1
- 24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET StudyCompletedNCT00818298Not applicable
- A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With SchizophreniaCompletedNCT00817648Phase 4
- Individually Based Psychosocial Rehabilitation for Older People With Serious Mental Illness (SMI)CompletedNCT00817154Phase 1
- D-serine Monotherapy for SchizophreniaCompletedNCT00816894Phase 2
- Examining Risk Factors for Atypical Antipsychotic Metabolic Side EffectsCompletedNCT00815854Not applicable
- Social Functioning in SchizophreniaCompletedNCT00814996
- The Effect of Intranasal Administration of Oxytocin on Empathic Abilities.Status unknownNCT00813436Phase 2
- Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With SchizophreniaCompletedNCT00810667Phase 2
- Contingency Management of Psychostimulant Abuse in the Severely Mentally IllCompletedNCT00809770Not applicable
- Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical TreatmentCompletedNCT00809731
- Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712CompletedNCT00805454Phase 1
- Change in Brain Bioenergetics in Bipolar Disorder in Response to Photic StimulationWithdrawnNCT00801567Not applicable
- Effect of Motivational Therapy on Schizophrenia With Cannabis MisuseCompletedNCT00798109Not applicable
- Quetiapine Related Neurochemical Changes as Measured by Magnetic Resonance Spectroscopy in SchizophreniaCompletedNCT00797927Phase 4
- A Dose-proportionality Study of Five Tablet Strengths of ER OROS PaliperidoneCompletedNCT00796835Phase 1
- A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release FormulationsCompletedNCT00796640Phase 1
- A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release FormulationsCompletedNCT00796471Phase 1
- A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS PaliperidoneCompletedNCT00796432Phase 1
- A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release PaliperidoneCompletedNCT00796276Phase 1
- As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release FormulationsCompletedNCT00796185Phase 1
- A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform DisorderCompletedNCT00796081Phase 1
- A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral DoseCompletedNCT00796029Phase 1
- Social Skills Training in Refractory SchizophreniaStatus unknownNCT00791882Not applicable
- A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ERCompletedNCT00791713Phase 1
- A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or QuetiapineCompletedNCT00791622Phase 1
- Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral TherapyCompletedNCT00791440Not applicable
- A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal FunctionCompletedNCT00791401Phase 1
- A Study of QT and QTc Intervals in Patients Administered Immediate Release PaliperidoneCompletedNCT00791349Phase 1
- A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver FunctionCompletedNCT00791284Phase 1
- A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With SchizophreniaCompletedNCT00791232Phase 1
- A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IRCompletedNCT00791193Phase 1
- A Study of the Dose Proportionality of Extended Release PaliperidoneCompletedNCT00791167Phase 1
- A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and VacavilleCompletedNCT00790777Phase 1
- Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in SchizophreniaStatus unknownNCT00789906
- Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic TreatmentStatus unknownNCT00789022
- Shiatsu Adjuvant Therapy And Placebo For SchizophreniaStatus unknownNCT00788970Not applicable
- Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Negative Symptoms in SchizophreniaCompletedNCT00783120Not applicable
- Four Dimensions in SchizophreniaCompletedNCT00782899
- Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic PatientsWithdrawnNCT00781794Phase 1